HQK 1001

Drug Profile

HQK 1001

Alternative Names: HQK-1001; ST-20

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HemaQuest Pharmaceuticals
  • Class Antianaemics; Small molecules; Volatile fatty acids
  • Mechanism of Action Erythropoiesis stimulants; Fetal haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 10 Jun 2013 HemaQuest completes enrolment in its phase IIb trial for Sickle cell anaemia (twice-daily dosing) in USA, Canada, Jamaica, Egypt & Lebanon (NCT01601340)
  • 31 Jan 2013 Boston University & HemaQuest complete a phase II trial in Beta-thalassaemia in Lebanon (NCT01642758)
  • 31 Jul 2012 Phase-II clinical trials in Sickle cell anaemia in Canada (PO, twice-daily dosing)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top